Tilray | TRLY - Current Assets


Tilray reported $729.32M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acasti Pharma USD 19.21M 1.91M Dec/2025
Akebia Therapeutics USD 243.48M 9.47M Mar/2026
Alaunos Therapeutics USD 970K 1.02M Mar/2026
Aurora Cannabis CAD 397.45M 48.38M Mar/2026
Avita Medical AUD 35.49M 760K Dec/2025
Canopy Growth CAD 529.47M 4.8M Mar/2026
Cronos Group USD 927.88M 16.21M Mar/2026
Dianthus Therapeutics USD 897.54M 222.37M Jun/2026
Divis Laboratories Ltd INR 110.96B 12.53B Mar/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
IQVIA Holdings USD 6.23B 6M Jun/2026
Knight Therapeutics CAD 394.84M 5.86M Dec/2025
Moderna USD 5.82B 45M Jun/2026
Organigram Holdings CAD 250.09M 6.46M Mar/2026
Organon & Co USD 4.93B 580M Mar/2026
Revvity USD 2.3B 169.4M Jun/2026
Tectonic Therapeutic USD 239.89M 17.47M Mar/2026
Tilray USD 729.32M 28.18M Sep/2025
Viatris USD 10.92B 1.13B Mar/2026
Xeris Pharmaceuticals USD 251.68M 11.37M Mar/2026
Zealand Pharma A/S 15.02B 652.12M Mar/2026